Mark Pimentel1. 1. GI Motility Program, Cedars-Sinai Medical Center, 8730 Alden Dr, Suite 225E, Los Angeles, CA 90048, USA. Mark.Pimentel@cshs.org
Abstract
BACKGROUND: Rifaximin is a broad-range, gastrointestinal-specific antibiotic that demonstrates no clinically relevant bacterial resistance. Therefore, rifaximin may be useful in the treatment of gastrointestinal disorders associated with altered bacterial flora, including irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO). OBJECTIVE: To review rifaximin for treatment of IBS and SIBO. METHODS: Review of rifaximin clinical trials. RESULTS/ CONCLUSION: Rifaximin improved global symptoms in 33 - 92% of patients and eradicated SIBO in up to 84% of patients with IBS, with results sustained up to 10 weeks post-treatment. Rifaximin caused a lower number of adverse events compared with metronidazole or levofloxacin and may have a more favorable adverse event profile than systemic antibiotics, without clinically relevant antibiotic resistance.
BACKGROUND:Rifaximin is a broad-range, gastrointestinal-specific antibiotic that demonstrates no clinically relevant bacterial resistance. Therefore, rifaximin may be useful in the treatment of gastrointestinal disorders associated with altered bacterial flora, including irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO). OBJECTIVE: To review rifaximin for treatment of IBS and SIBO. METHODS: Review of rifaximin clinical trials. RESULTS/ CONCLUSION:Rifaximin improved global symptoms in 33 - 92% of patients and eradicated SIBO in up to 84% of patients with IBS, with results sustained up to 10 weeks post-treatment. Rifaximin caused a lower number of adverse events compared with metronidazole or levofloxacin and may have a more favorable adverse event profile than systemic antibiotics, without clinically relevant antibiotic resistance.
Authors: Jan Bures; Jiri Cyrany; Darina Kohoutova; Miroslav Förstl; Stanislav Rejchrt; Jaroslav Kvetina; Viktor Vorisek; Marcela Kopacova Journal: World J Gastroenterol Date: 2010-06-28 Impact factor: 5.742